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ABSTRACT: Mesenchymal stromal (stem) cells have potential in regenerative medicine and modulating the immune system. To
deliver any cell-based therapy to the patient, it must be cryopreserved, most commonly in DMSO, which impacts cell function and
causes clinical side effects. Here we report the use of a synthetically scalable polyampholyte to rescue the cryopreservation of
mesenchymal stromal cells in low [DMSO] cryopreservation. Flow cytometry showed retention of key markers of multipotency
comparable to 10% (v/v) DMSO, and the cells could be differentiated, showing this polymer material can be used to improve, or
replace, current cryopreservation strategies.
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Mesenchymal stromal (stem) cells (MSC) have hugepotential as regenerative therapies for a range of
indications from treating fibrosis, rescuing heart function,
and modulating the immune system.1 A key aspect in the
development of MSC treatments is producing and storing large
quantities of cells, since they have a limited lifetime in vitro
and cannot be continuously cultured due to phenotype drift.2
Isolated cells must be transported to special processing
facilities, expanded and, crucially, cryopreserved for storage
and transport to clinics. To enable future clinical therapies to
succeed, it is imperative that cell characteristics are recovered
after cryopreservation. Current methods to store MSCs (and
most cells) rely on high volumes (10% v/v) of dimethyl
sulfoxide (DMSO), which has been shown to cause phenotypic
changes in stem cells3 and can induce differentiation in
embryonic stem cells at concentrations as low as 0.125%.4
More critically, DMSO is known to cause adverse side effects
in patients receiving cell therapies, ranging from mild
symptoms, such as nausea,5 to seizures and cardiac arrest.6 A
study reported one in 70 transfusions result in DMSO-related
side effects.7
As a result, there is interest in the development of
cryoprotective agents that can reduce the amount of DMSO
in the cryoprotective solution while recovering large numbers
of viable cells and retaining cell-specific functions. In the case
of stem cells, this means preserving stem cell characteristics
such as specific surface markers and differentiation capacity.
Alternative cryopreservation methods include using other small
molecules such as glycerol and trehalose,8 or through
vitrification whereby large volumes of solvent are used to
achieve a glassy state without ice formation. However, vitreous
states can be unstable, leading to ice nucleation followed by
catastrophic ice growth, and the high concentrations of
solvents required can lead to toxicity.9
As an alternative to the traditional small-molecule-based
cryoprotectants, macromolecular (polymer/protein) cryopro-
tectants are emerging,10,11 inspired by ice binding,12 ice
nucleating,13 and late embryogenesis abundant proteins14
found in nature. The function of macromolecular cryopro-
tectants includes ice recrystallization inhibition (IRI) activity15
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or potentially osmotic regulation.17 One emerging class of
macromolecular cryoprotectants is polyampholytes, which
contain both cationic and anionic side chains, which have
been shown to be potent cryoprotectants. Their mechanism of
action remains unclear, but it has been suggested to involve
membrane stabilization.16 Polyampholytes are reported to
exhibit some IRI activity,18 but it is weak when compared to
potent IRI active polymers, such as PVA.19 Matsumura et al.
have used polyampholytes to vitrify induced pluripotent stem
cells (iPSC) by using 10% (w/v) polymer along with 6.5 M
ethylene glycol and 0.75 M sucrose.20 Recoveries of >60%
could be achieved when cells were incubated for 30 s with the
vitrification solution, but this was more than halved when
incubation times were extended to 120 s, due to the toxicity of
such high volumes of solvent. In contrast, cell cryopreservation
has been achieved with polyampholytes using slow-cooling
methods, which are desirable due to low solvent concen-
trations, sample stability, and straightforward processes. We
recently reported a polyampholyte cryoprotectant that was a
potent additive for the cryopreservation of cell monolayers
(demonstrated in multiple immortalized cell lines) using slow-
cooling, which is an extremely challenging model.21
Here, we study the scope and limitations of this synthetically
scalable polyampholyte to cryopreserve mesenchymal stromal
cells in suspension. It is shown that the polymer allows
successful cryopreservation at just 2.5% (v/v) DMSO and that
the recovered cells are viable, retain all “stem-like” markers,
and are capable of differentiation into various lineages.
The polyampholyte (cryoprotectant) was synthesized by the
reaction of poly(methyl vinyl ether-alt-maleic anhydride) with
dimethylamino ethanol (Figure 1A). Both components are low
cost and available to GMP (good manufacturing practice)
grade, on a scale necessary for a new cryoprotectant to be
useful. This point is essential as just one liter of cells would
require ∼100 g of a cryoprotectant at 10% (w/v) and hard-to-
synthesize or peptide-based materials are typically not available
at this scale. The use of a maleic anhydride precursor polymer
also guarantees an alternating monomer sequence due to its
propensity to cross-propagate and a 1:1 cationic/anionic ratio
(crucial for cryopreservation success), which cannot be
achieved by random copolymerization.22 This polymer is a
potent cryoprotectant for cell monolayers;21 its mode of action
does not involve vitrification, and it has only weak ice
recrystallization inhibition activity, with evidence that it can
stabilize cell membranes.16,21
Human bone marrow-derived mesenchymal stromal (stem)
cells (hBM-MSC) were initially screened for cryopreservation
conditions (Figure S1). Cells were cooled at 1 °C min−1 to
−80 °C, transferred to liquid nitrogen for 24 h then thawed at
37 °C in a water bath, plated, and allowed to recover for 24 h
before analysis. Initial cryopreservation screens used 1 × 105
cells mL−1 and variable concentrations of DMSO/polyampho-
lyte. This analysis revealed that 20 mg mL−1 of the
polyampholyte was needed to enable a reduction in the
DMSO to 2.5% (v/v) but that the total number of cells
recovered post-thaw was rather low (<10% recovered). From
this point, an increased cell density of 5 × 105 cells mL−1 was
used, as this gave close to 50% recovery in standard (10% (v/
v) DMSO) conditions.
Figure 2 shows the results of the optimized hBM-MSC
cryopreservation. When the concentration of DMSO was
reduced from 10 to 2.5% (v/v), the post-thaw viability of
hBM-MSC dropped from 92 to 47% (Figure 2A), highlighting
why such high concentrations of DMSO are essential to
protect the cells. However, upon supplementing with 20 mg
mL−1 polyampholyte, the viability was rescued to 76%,
demonstrating that the polyampholyte is a potent cryopro-
tectant. Antebi et al. reported the 24 h post-thaw viability of
MSC frozen with 10% DMSO to be ∼80%, highlighting that
supplementation with our polyampholyte can achieve the same
results but using just a quarter of the [DMSO].23 In a clinical
Figure 1. (A) Synthesis of polyampholyte. (B) Cryopreservation
protocol for hBM-MSC slow freezing method and analysis.
Figure 2. hBM-MSC post-thaw recovery after 24 h. (A) Cell viability.
(B) Total number of cells recovered, polymer indicates 20 mg mL−1
polyampholyte. Viability and recovery data are expressed as mean ±
SEM for three independent experiments. Statistical analysis by one-
way ANOVA, * = p < 0.05, ** = p < 0.0001. Light microscope images
of cells 24 h post-thaw when frozen with (C) 10% (v/v) DMSO, (D)
2.5% (v/v) DMSO, (E) 2.5% DMSO (v/v) + 20 mg mL−1
polyampholyte. Scale bar indicates 100 μm. Flow cytometry data
showing forward and side scatter of thawed hBM-MSCs; (F) 10%
DMSO (v/v), (G) 2.5% DMSO (v/v) + 20 mg mL−1 polyampholyte.
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context, this is a highly desirable achievement, as lowering the
DMSO content of transfused stem cells has been shown to
reduce the incidence of adverse clinical side effects 5-fold.7
Critically, we have reported 24 h post-thaw results as MSCs
require 24 h post-thaw to regain function and enable true
evaluation of recovery.23 This point is crucial to show the
impact of this work; Zhao et al. reported post-thaw viabilities
of ∼90% when freezing 3T3 cells with polyampholytes.
However, the majority of cells died after 24 h in culture.17
Similarly, Naaldijk et al. reported immediate post-thaw
viabilities of MSC frozen with DMSO and hydroxyethyl starch
to be ∼85%, but this plummeted to <30% after 3 days in
culture for samples containing <4% DMSO.24 These studies
highlight that immediate post-thaw viability is not a good
predictor of cell health.25
While viability is the most widely reported measure of
cryopreservation, it does not consider the fraction of cells lost
due to lysis and mechanical damage. Therefore, the post-thaw
total cell recovery values (which compare the number of cells
initially frozen to the number of live cells present after
thawing) were measured (Figure 2B). When frozen with 10%
(v/v) DMSO, 51% of hBM-MSCs were recovered 24 h post-
thaw. This dropped to just 17% when 2.5% (v/v) DMSO was
used as the cryoprotectant. The addition of 20 mg mL−1
polyampholyte doubled the post-thaw recovery to 30%, clearly
seen with microscopy of cells 24 h post-thaw (Figure 2C−E).
Very few other studies count recovered cells. However,
Petrenko et al. reported that 5% DMSO led to cell recoveries
of <25% in hematopoietic stem cells,26 and Verdanova et al.
showed that 5% DMSO gave 36% recovery of human MSCs.27
This clearly highlights that our polyampholyte enables a
significant improvement in both the viability and recovery of
hBM-MSC at low concentrations of DMSO.
Flow cytometry of thawed cells revealed minimal differences
in both size (forward scatter) and granularity (side scatter)
when comparing cells subjected to freezing in 10% versus 2.5%
(v/v) DMSO supplemented with 20 mg mL−1 polyampholyte
(Figure 2F,G). Under all conditions, approximately 90% of all
recovered cells were located within the gated viable cell region.
Thus, supplementation of this polyampholyte to cryopreserva-
tion solutions clearly leads to post-thaw recovery of intact cells,
using significantly reduced [DMSO].
The above showed that large numbers of viable cells are
recovered when the polyampholyte was included, but it is
crucial to demonstrate MSC function, especially for biomedical
applications. Therefore, thawed hBM-MSCs were assessed for
the presence of stem cell surface markers that indicate
multipotency: CD90, CD105, and CD146, as well as the
absence of CD45 (negative marker, not present on MSCs).28
Surface marker expression was studied using antibodies
conjugated to fluorescent dyes and analyzed by flow cytometry.
All samples were compared to non-frozen controls (Figure 3)
and isotype controls (Figure S3). In comparison to non-frozen
antibody untreated (−Ab) hBM-MSC controls, a clear
enhancement in the fluorescence intensity of positive stem
cell surface markers was observed in non-frozen antibody-
treated (+Ab) hBM-MSC controls and hBM-MSCs frozen in
10% (v/v) DMSO, 2.5% (v/v) DMSO, and 2.5% (v/v) DMSO
plus polyampholyte. However, no change was seen when the
same cells were treated with anti-CD45 antibodies, demon-
strating the absence of this negative marker. Crucially, no
significant changes to the mean fluorescence intensity of cells
frozen in the different cryoprotectants were observed
compared to nonfrozen + Ab hBM-MSC controls, Figure S4,
indicating that freezing in DMSO and polyampholyte does not
significantly change the expression of stem cell surface markers
and hence the multipotent identity of hBM-MSCs.
As a final test, differentiation experiments were undertaken
to understand if the cells retained their multilineage capacity.
Immediately after thawing, cells were added to gelatin-coated
plates and incubated for 24 h before treatment with either
osteogenic differentiation media or adipogenic differentiation
media for 2−3 weeks. Following incubation, cells were stained
with Alizarin Red S for the presence of calcium deposits
produced by osteoblasts and Oil Red O to identify lipid
droplets present in adipocytes, Figure 4. All samples treated
with osteogenic differentiation media showed clear differ-
entiation into an osteoblast (bone) cell phenotype as
demonstrated by extensive calcium deposits, stained bright
red by Alizarin Red S staining, Figure 4. Negligible differences
could be identified between samples cryopreserved in each of
the different cryopreservation solutions as well as the
nonfrozen control. Calcium deposits were absent in undiffer-
entiated control cells, showing there was no premature/
spontaneous differentiation. Similarly, all samples treated with
adipogenic differentiation media displayed an adipocyte (fat)
cell phenotype, indicated by the presence of lipid droplets that
Figure 3. Flow cytometry analysis of immunostained hBM-MSCs
frozen in the presence of 10% (v/v) DMSO, 2.5% (v/v) DMSO, and
2.5% DMSO (v/v) + 20 mg mL−1 polyampholyte. Recovered cells
were immunostained for cell surface markers using 3 positive markers
(CD90-APC, CD105-PerCP, and CD146-CFS) and 1 negative
marker (CD45-PE). Nonfrozen hBM-MSCs, both unstained (−Ab)
and stained (+Ab), were provided as controls to observe changes in
fluorescence intensity.
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were stained positively with Oil Red O, as well as a flattened
cell morphology. Again, no difference was found between
nonfrozen samples and samples cryopreserved with the three
cryoprotectants. Oil Red O staining was absent for
undifferentiated control cells. Figure 4 clearly demonstrates
that hBM-MSC cryopreserved in the presence of the
polyampholyte is capable of differentiating into both osteoblast
(bone) and adipocyte (fat) cells, giving the same results as cells
cryopreserved in 10% (v/v) DMSO but with a quarter of the
permeable cryoprotectant.
In summary, we have demonstrated that a polyampholyte,
which is obtained on a large scale from a commodity polymer
precursor, allows the use of significantly lower DMSO
concentrations for human mesenchymal stromal (stem) cell
(hBM-MSC) cryopreservation. Just 20 mg mL−1 of the
polyampholyte enabled the rescue of MSC cryopreservation
when the DMSO was lowered from the standard 10% (v/v) to
just 2.5% (v/v). Flow cytometry analysis confirmed that the
stromal/stem cell surface markers CD90, CD105, and CD146
were all retained and were statistically identical between cells
stored in 10% (v/v) DMSO, compared to 2.5% (v/v) DMSO
+ polyampholyte. Furthermore, the thawed cells were
successfully differentiated into osteogenic and adipocyte
lineages, confirming their “stemness”. These results show
that significant reductions in DMSO concentration can be
achieved in biomedically relevant cell lines by using
polyampholytes and, importantly, do not require large solvent
volumes associated with vitrification, which has been reported
for other macromolecular cryoprotectants. We also show an
improvement in the total number of cells being recovered,
compared to the standard method where only the viability is
reported, which can overestimate the cryopreservation out-
come. These results will aid the development of advanced
cryoprotective formulations for cell-based therapies as well as
basic biomedical science.
■ EXPERIMENTAL SECTION
Full details of experimental procedures are given in the Supporting
Information. Polyampholyte was synthesized as previously de-
scribed.21
Cryopreservation of Cell Suspensions. The polymer was
dissolved in culture media containing 60% FBS and 5% DMSO, at 2×
the final concentration, and then sterile-filtered through a 0.2 μm
membrane. Cells were treated with Accutase for 10 min at room
temperature, neutralized with complete cell media, and centrifuged for
5 min at 180g. Following centrifugation, cells were diluted 1:1 with
0.4% trypan blue and counted with a hemocytometer to obtain the
number of viable cells. The cell density was adjusted to 1 × 106 cells
mL−1, and a second cell count was performed to obtain an accurate
prefreeze value. Cells were diluted 1:1 in cryoprotectant in cryovials
(total volume 1 mL) and mixed 3 times. Triplicate samples were
prepared for each cryopreservation solution: 10% DMSO, 2.5%
DMSO, or 2.5% DMSO + 20 mg mL−1 polyampholyte, all containing
30% FBS. The vials were placed in a CoolCell freezing box in a −80
°C freezer for 2 h, with a freezing rate of 1 °C min−1. After 2 h, the
vials were transferred to a liquid nitrogen dewar for a minimum of 24
h. To thaw, vials were placed in a 37 °C water bath until nearly
thawed; then, the contents were diluted 1:10 in complete cell culture
media and centrifuged at 180g for 5 min. Cells were resuspended in
500 μL complete cell media and then transferred to individual wells of
a 0.1% gelatin-treated 24-well plate. Plates were incubated at 37 °C
and 5% CO2 for 24 h. After 24 h, total cell recovery and cell viability
were assessed by the trypan blue exclusion assay.
Trypan Blue Exclusion Assay. Cells were treated with Accutase
for 10 min at room temperature and then centrifuged at 180g for 5
min. The cell pellet was resuspended in 500 μL complete media; then,
a sample was diluted 1:1 in 0.4% trypan blue and counted using a
hemocytometer. Cell viability and cell recovery were determined
using the two equations, where cell viability is the number of
unstained cells post-thaw compared to the total cells post-thaw and
Figure 4. hBM-MSC differentiated toward osteoblast (osteogenesis) and adipocyte (adipogenesis) phenotypes and stained with Alizarin Red S and
Oil Red O, respectively. Scale bar, 100 μm. Images show the same sample before and after staining. Undifferentiated and differentiated nonfrozen
controls were included for comparison. Remaining samples were cryopreserved with 10% (v/v) DMSO, 2.5% (v/v) DMSO, or 2.5% (v/v) DMSO
+ 20 mg mL−1 polyampholyte.
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where cell recovery is the number of unstained cells post-thaw
compared to the total cells initially frozen.
viability (%)
cells
cells cells
100TB
unstained
unstained stained
=
+
×
recovery (%)
cells
cells
100TB
unstained
frozen
= ×
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D. H. Synthetic Polyampholytes as Macromolecular Cryoprotective
Agents. Langmuir 2019, 35 (5), 1807−1817.
(18) Mitchell, D. E.; Lilliman, M.; Spain, S. G.; Gibson, M. I.
Quantitative Study on the Antifreeze Protein Mimetic Ice Growth
Inhibition Properties of Poly(Ampholytes) Derived from Vinyl-Based
Polymers. Biomater. Sci. 2014, 2 (12), 1787−1795.
(19) Gibson, M. I.; Barker, C. A.; Spain, S. G.; Albertin, L.;
Cameron, N. R. Inhibition of Ice Crystal Growth by Synthetic
Glycopolymers: Implications for the Rational Design of Antifreeze
Glycoprotein Mimics. Biomacromolecules 2009, 10 (2), 328−333.
(20) Matsumura, K.; Bae, J. Y.; Kim, H. H.; Hyon, S. H. Effective
Vitrification of Human Induced Pluripotent Stem Cells Using
Carboxylated ε-Poly-l-Lysine. Cryobiology 2011, 63 (2), 76−83.
(21) Bailey, T. L.; Stubbs, C.; Murray, K.; Tomaś, R. M. F.; Otten,
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